Used in pharmaceutical synthesis as an intermediate for producing selective estrogen receptor modulators (SERMs). It plays a key role in the development of drugs targeting hormone-dependent conditions such as breast cancer and osteoporosis. The compound's structure, featuring an Fmoc-protected chiral amine derived from tetrahydronaphthalene, allows for chiral specificity and enhanced binding affinity in final active pharmaceutical ingredients. Commonly employed in research settings for optimizing drug candidates with improved metabolic stability and tissue selectivity.